https://www.selleckchem.com/
Ulipristal may be associated with DILI resulting in a risk of severe liver injury in 1.5100 000 patients and fatal liver injury in 0.1100 000 patients. This risk needs to be weighed against the higher mortality risk of 11000 and higher incidence of severe complications after surgery. The DILI risk of ulipristal is considerably lower than that of other medicines that are not suspended, nor need additional safety measures. When evaluating drugs and drug safety, risks that apply to the alternative nonpharmacological treatment options should be taken into c
Like
Comment
Share
